New weapon against advanced cancer begins human testing
NCT ID NCT07424547
Summary
This is a first-in-human study to test a new investigational drug called SYS6043 in adults with advanced or metastatic solid tumors that have spread or no longer respond to standard therapies. The main goals are to find a safe dose, understand the drug's side effects, and see how it moves through the body. Researchers will also look for early signs that the drug may help slow or shrink tumors, especially in cancers with a specific protein called B7-H3.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BRCR Global
RECRUITINGPlantation, Florida, 33322, United States
Contact Phone: •••-•••-••••
-
Florida Clinical Trials Group
RECRUITINGPlantation, Florida, 33322, United States
Contact Phone: •••-•••-••••
-
NEXT Oncology Austin
RECRUITINGAustin, Texas, 78758, United States
Contact Phone: •••-•••-••••
-
NEXT Oncology San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-••••
-
NEXT Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.